Antonia Salud Salvia

Diaz-Serrano, A; Angulo, B; Dominguez, C; Pazo-Cid, R; Salud, A; Jimenez-Fonseca, P; Leon, A; Galan, MC; Alsina, M; Rivera, F; Plaza, JC; Paz-Ares, L; Lopez-Rios, F; Gomez-Martin, C

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab

Oncologist 23 1092-1102. 01/09/2018.

[doi:10.1634/theoncologist.2017-0379]

Alonso, V; Escudero, P; Fernandez-Martos, C; Salud, A; Mendez, M; Gallego, J; Rodriguez, JR; Martin-Richard, M; Fernandez-Plana, J; Manzano, H; Mendez, JC; Zanui, M; Falco, E; Gil-Raga, M; Rojo, F; Cuatrecasas, M; Feliu, J; Garcia-Albeniz, X; Maurel, J

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients

NEOPLASIA 20 678-686. 01/07/2018.

[doi:10.1016/j.neo.2018.05.004]

Feliu, J; Salud, A; Losada, EP; Alonso, V; Cubillo, A; Soler, G

First-line treatment with panitumumab plus FOLFIRI in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.

Journal of Clinical Oncology 36 -. 20/05/2018.

[doi:10.1200/JCO.2018.36.15_suppl.TPS3618]

Codony-Servat, J; Cuatrecasas, M; Asensio, E; Montironi, C; Martinez-Cardus, A; Marin-Aguilera, M; Horndler, C; Martinez-Balibrea, E; Rubini, M; Jares, P; Reig, O; Victoria, I; Gaba, L; Martin-Richard, M; Alonso, V; Escudero, P; Fernandez-Martos, C; Feliu, J; Mendez, JC; Mendez, M; Gallego, J; Salud, A; Rojo, F; Castells, A; Prat, A; Rosell, R; Garcia-Albeniz, X; Camps, J; Maurel, J

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

BRITISH JOURNAL OF CANCER 117 1777-1786. 05/12/2017.

[doi:10.1038/bjc.2017.279]

Porcel, JM; Sole, C; Salud, A; Bielsa, S

Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion

Lung 195 775-779. 01/12/2017.

[doi:10.1007/s00408-017-0050-1]

Vallez-Valero, L.; Rius-Perera, J.; Gilabert Sotoca, M.; Mangues-Bafalluy, I; Schoenenberger, J. A.; Salud-Salvia, M. A.

USE OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT-PROSTATE CANCER IN ROUTINE CLINICAL PRACTICE

VALUE IN HEALTH 20 417-417. 01/10/2017.

[doi:10.1016/j.jval.2017.08.114]

Sastre, J.; de la Orden, V.; Martinez, A.; Bando, I.; Santamaria, I.; Bellosillo Paricio, B.; Palanca, S.; Peligros, I.; Mediero, B.; Llovet, P.; Moreno, V.; Vieitez, J. M.; Garcia-Alfonso, P.; Gil, S.; Ortiz Morales, M. J.; Salud Salvia, M. A.; Quintero, G.; Gesto, F. A.; Aranda Aguilar, E.; Diaz Rubio, E.

Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISN & Uacute; Program

ANNALS OF ONCOLOGY 28 -. 01/09/2017.

Novell, A; Morales, S; Valls J; Panades, MJ; Salud, A; Iglesias, E; Vilardell, F; Matias-Guiu, X; Llombart-Cussac, A

Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases

HISTOLOGY AND HISTOPATHOLOGY 32 909-915. 01/09/2017.

[doi:10.14670/HH-11-849]

Salazar, R.; Azuara, D.; Vieitez, J. M.; Paez, D.; Santos, C.; Falco, E.; Elez, E.; Lopez Lopez, C.; Valladares-Ayerbes, M.; Robles, L.; Garcia-Alfonso, P.; Buges, C.; Ogaya, G. Duran; Salud Salvia, M. A.; Navarro, V.; Capella, G.; Aranda Aguilar, E.

ULTRA clinical trial: Prospective comparative clinical outcome analysis of three different RAS/BRAF sensitivity mutational cut-offs. A Phase II study of the Spanish TTD Group

ANNALS OF ONCOLOGY 28 -. 01/09/2017.

Porcel, JM; Civit, C; Esquerda, A; Salud, A; Bielsa, S

Utility of CEA and CA 15-3 measurements in non-purulent pleural exudates in the diagnosis of malignancy: A single-center experience

ARCHIVOS DE BRONCONEUMOLOGIA 53 427-431. 01/08/2017.

[doi:10.1016/j.arbres.2016.12.013]

Pineda, E; Salud, A; Vila-Navarro, E; Safont, MJ; Llorente, B; Aparicio, J; Vera, R; Escudero, P; Casado, E; Bosch, C; Bohn, U; Perez-Carrion, R; Carmona, A; Ayuso, JR; Ripolles, T; Bouzas, R; Gironella, M; Garcia-Albeniz, X; Feliu, J; Maurel, J

Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

TUMOR BIOLOGY 39 -. 16/06/2017.

[doi:10.1177/1010428317705509]

Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E

Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group

EUROPEAN JOURNAL OF CANCER 75 73-82. 01/04/2017.

[doi:10.1016/j.ejca.2016.12.032]